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Abstract
Background:  The emergence of Plasmodium falciparum resistant to most currently used
antimalarial drugs is the major problem in malaria control along the Thai-Myanmar and Thai-
Cambodia borders. Although artemisinin-based combination therapy has been recommended for
the treatment of multidrug-resistant falciparum malaria, these combinations are not available for
some people, such as travelers from North America. A fixed-dose combination of atovaquone and
proguanil (Malarone) has been proved to be effective for the treatment and prophylaxis of malaria
which is already approved by countries in North America and Europe. Determination of the
phenotypes and genotypes related to atovaquone/proguanil response in Thai isolates of P.
falciparum will be useful for rationale drug use. The main purpose of this study was to explore the
in vitro atovaquone/proguanil susceptibility of recently adapted Thai isolates of P. falciparum.
Genotypic characterization of the cytb gene of these isolates was also determined since it has been
reported that point mutations, particularly codon 268 in the cytochrome b gene (cytb) have been
linked to atovaquone/proguanil treatment failure.
Methods: Eighty three P. falciparum isolates collected during 1998 to 2005 from four different
multidrug resistance areas of Thailand were determined for the in vitro atovaquone/proguanil
susceptibilities using radioisotopic assay. Mutations in the cytb gene were determined by PCR-RFLP
and sequence analysis.
Results: The mean atovaquone and proguanil IC50 was 3.4 nM and 36.5 μM, respectively. All 83
Thai isolates were atovaquone sensitive. None of the 83 isolates contained the mutations at codon
268 of the cytb gene. DNA sequencing of the cytb gene of 20 parasite isolates showed no other
mutations.
Conclusion: In agreement with a recent efficacy study of atovaquone/proguanil, the present
information indicates that atovaquone/proguanil can be one of the drugs of choice for the
treatment and prophylaxis of multidrug-resistant falciparum malaria in Thailand.
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Background
Multidrug-resistant falciparum malaria is a major health
problem along Thai-Myanmar and Thai-Cambodia bor-
ders. WHO has recommended artemisinin-based combina-
tion therapy as the first-line treatment for uncomplicated
falciparum malaria in these multidrug resistance areas. In
Thailand, a combination of artesunate and mefloquine has
been used for more than 10 years. Recently, reduced effi-
cacy of this combination has been reported from Thai-
Cambodia border [1]. Effective chemoprophylaxis for
malaria in these multidrug resistance areas is also needed
especially for non-immune travelers. Thus the alternative
drugs or drug combinations should be considered. Malar-
one® is a fixed-dose combination of atovaquone and pro-
guanil. It is highly effective for the treatment and
prophylaxis of multidrug-resistant falciparum malaria
[2,3]. Atovaquone exerts its action via inhibiting plasmo-
dial mitochondria electron transport at the level of the cyto-
chrome bc1  complex and collapsing mitochondrial
membrane potential [4,5]. In addition, it inhibits dihy-
droorotate dehydrogenase (DHOD) enzyme which cataly-
ses the reaction from dihydroorotate to orotate [6].
Therefore, atovaquone can inhibit both nucleic acid and
ATP synthesis. Proguanil was added for the synergistic
effect which is probably due to enhancing atovaquone to
collapse mitochondrial membrane potential [7].
A few cases of atovaquone-proguanil (AP) treatment fail-
ure have been reported, mainly from Africa [8-16]. Treat-
ment failure of AP in these patients was due to
atovaquone resistance and has been linked to point muta-
tions in the target gene of atovaquone, Plasmodium falci-
parum mitochondrial cytb gene, i.e. Tyr268Ser, Tyr268Asn
and Tyr268Cys. Codon 268 of the cytb gene is a region
encoding the putative atovaquone-binding domain [17].
Tyrosine (Y) at position 268 is conserved bulky hydro-
phobic contact of the drug in the Qo II region of the ubi-
quinol oxidation site. Substitution of serine (S), a
hydrophilic amino acid, limits hydrophobic contact with
atovaquone. This reason explains the marked decrease in
atovaquone susceptibility in mutated malaria parasites
[8,17]. Substitution of the less bulky asparagine (N) at
position 268 not only reduced the volume of the binding
pocket but it also decreases the affinity and binding of
atovaquone [8]. Thus, these mutations are considered as
the main markers for the surveillance of AP resistance. To
date, AP has not been routinely used for the treatment and
prophylaxis of falciparum malaria in Thailand. However,
recent study showed a high efficacy of AP for the treat-
ment of multidrug-resistant falciparum malaria on Thai-
land-Myanmar border [18]. This combination may be
considered as the alternative drugs for the treatment and
prophylaxis of malaria especially for western non-
immune travelers. However, surveillance of AP resistance
at the phenotypic and genotypic levels is necessary before
this combination is recommended. Since recent report
showed that AP-resistant genotype of P. falciparum can be
detected in the non-exposed area. Happi et al found
Tyr268Asn mutation in P. falciparum from Nigeria where
AP has not been used; his finding suggests that the muta-
tions in the cytb  gene might naturally occur [19]. This
study aimed to determine the in vitro atovaquone and pro-
guanil sensitivity of adapted Thai isolates of P. falciparum
from four different endemic areas. Genotypic characteri-
zation of the cytb  gene of these isolates was also per-
formed.
Methods
Malaria parasites
Eighty three isolates of P. falciparum were collected from
four endemic areas along Thai-Myanmar border (Tak,
Kanchanaburi and Ranong) and Thai-Cambodia border
(Chantaburi) during 1998 to 2005. These isolates were
adapted and cryopreserved in liquid nitrogen before used.
Parasites were cultivated continuously in vitro by a modi-
fication of Trager and Jensen method [20].
In vitro drug sensitivity assay
In vitro atovaquone and proguanil susceptibility of these
Thai isolates of P. falciparum was determined using modi-
fied radioisotopic method of Desjardins et al [21]. Both
atovaquone and proguanil were kindly provided by
Stephen A Ward (Liverpool School of Tropical Medicine,
UK). Atovaquone was dissolved in dimethylsulfoxide
(DMSO), whereas proguanil was dissolved in 50% etha-
nol. The IC50 was eventually evaluated using the GRAFIT®
programme (Erithacus Software Ltd., UK). The IC50 value
of each isolate was the mean of at least three independent
experiments. Comparisons of the IC50 values of parasites
collected in different years and from different areas were
analyzed using One-way ANOVA. The level of significance
was set at p < 0.05.
PCR-RFLP for detection of mutations in the cytb gene
P. falciparum DNA was isolated using chelex-resin as
described by Wooden et al [22]. PCR-RFLP was performed
to determine the three known polymorphisms at codon
268 of the cytb gene using primers CYTB3/CYTB5, CYTB2/
CYTB6 and CYTB2/CYTB7 as previously described [9]. For
RFLP analysis, the PCR products of each pair of primers
were digested with NsiI, AlwNI and SspI, respectively (New
England Biolabs, UK). NsiI cut the wild type and asparag-
ine mutation. AlwNI cut the serine mutation while SspI cut
wild type and serine mutation but not the asparagine
mutation. The digested PCR products were subsequently
analyzed by agarose gel electrophoresis.
DNA sequencing of the cytb gene
Since the point mutations in the cytb gene at the codons
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to be involved with atovaquone sensitivity, DNA sequenc-
ing of the cytb gene was also performed. Twenty isolates
were randomly selected from 83 isolates collecting from
different years and endemic areas. These 20 isolates also
represented parasites with the highest and lowest
atovaquone IC50 values. The primers pair of CYTB1 and
CYTB2 was used for PCR amplification. The PCR products
were sequenced by Macrogen Inc, Korea.
Results and Discussion
In vitro atovaquone and proguanil susceptibility
The mean atovaquone IC50 values of P. falciparum isolates
in this study was 3.4 ± 1.6 (0.83–6.81 nM). While, the
mean proguanil IC50 values was 36.5 ± 7.0 (21.2–49.6).
The atovaquone and proguanil IC50 values of P. falciparum
isolates obtained in various years and from various
endemic areas were shown in Figure 1 and 2, respectively.
The mean ± SD of atovaquone IC50 values in 1998, 2000,
2002, 2003 and 2005 were 3.4 ± 1.6, 2.8 ± 1.6, 3.8 ± 1.5,
3.2 ± 1.6 and 2.0 ± 0.8 nM, respectively. The mean ± SD
of proguanil IC50 values in 1998, 2000, 2002, 2003 and
2005 were 39.9 ± 7.8, 34.8 ± 5.1, 39.2 ± 7.4, 33.8 ± 5.9
and 29.8 ± 7.9 μM, respectively. The mean ± SD of
atovaquone IC50 value from Tak, Kanchanaburi, Ranong
and Chantaburi were 3.4 ± 1.6, 3.3 ± 1.6, 2.9 ± 1.5 and 2.6
± 1.6 nM, respectively. The mean ± SD of proguanil IC50
value from Tak, Kanchanaburi, Ranong and Chantaburi
were 36.7 ± 7.28, 35.0 ± 9.3, 34.9 ± 4.3 and 31.7 ± 4.7 μM,
respectively. The cut-off point used for atovaquone sensi-
tive and atovaquone resistance was the IC50 of <30 nM
and >1900 nM, respectively [15]. Based on these criteria,
all 83 Thai isolates were sensitive to atovaquone.
Although the mean atovaquone IC50 value of these Thai
isolates was apparently higher than African isolates
[15,23], this IC50 value (3.2 nM) was still classified in the
range of atovaquone sensitive. Futhermore Gay et al deter-
mined the correlation of atovaquone and other antimalar-
ial drugs in parasites isolated from the Philippines and
found the significant correlations between of the IC50 of
atovaquone and chloroquine, quinine, mefloquine,
artemisinin and its derivatives [23]. The sensitivity of 83
isolates to other drugs was also determined and showed
that there was no correlation among atovaquone and
chloroquine, quinine, mefloquine and dihydroartemisi-
nin IC50. The absence of the correlation of atovaquone
and most available drugs in these isolates is a good evi-
dence for the possibility of using AP as the alternative
antimalarial drug in Thailand.
In this study, both atovaquone and proguanil sensitivity
of these isolates were gradually decreased over the seven
years of collection period. There were significantly differ-
ences between the proguanil IC50 values in the years 1998
and 2005 (p = 0.021) and in the year 2002 and 2005 (p =
0.020). There was no difference of the atovaquone and
proguanil IC50 values among the isolates adapted from
different endemic areas.
PCR-RFLP and sequencing
Regarding to atovaquone, it has been reported that the
mutations in the cytb gene especially at the codon 268 is
responsible for atovaquone resistance [8-16]. In this study,
all isolates were identified as wild-type genotype of the cytb
gene at the codon 268. Sequence analysis also confirmed
that all selected 20 isolates had a wild-type cytb gene at the
codon 268. Recent studies showed a low prevalence of pol-
ymorphisms at the codon 268 [13,24]. These point muta-
tions at the codon 268 seems to be sufficient, but not
Box plots of atovaquone and proguanil IC50 of parasite isolates collected in different years Figure 1
Box plots of atovaquone and proguanil IC50 of parasite isolates collected in different years.
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necessary, for AP treatment failure since the point muta-
tions at this position were not identified in every treatment
failure cases [13]. Other mutations i.e. M133I and V284K
have been also linked to atovaquone resistance. From
sequence analysis, there was no M133I and V284K muta-
tion in all 20 isolates. The results of DNA sequencing were
accorded well with the results of in vitro drug sensitivity
assay and suggested that there was no atovaquone-resistant
phenotype and genotype in these Thai isolates of P. falci-
parum. Similar results were previously reported in a study of
parasite isolates from Thai-Myanmar border by Naoshima-
Ishibashi et al; all samples showed no mutations at the
codon 268 of the cytb gene [25].
A recent efficacy study also showed that AP remained
highly efficacious for the treatment of multidrug-resistant
falciparum malaria in Thailand [18]. From both in vitro
and in vivo information, AP can be considered as the drug
of choice for the treatment and prophylaxis of falciparum
malaria in Thailand.
Conclusion
The evidence from our study strongly supports the possi-
bility of AP as an alternative antimalarial drug for the
treatment and prophylaxis of multidrug-resistant falci-
parum malaria in Thailand.
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